Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06853015 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Mar 2026 to Mar 1, 2026
    • Study completion date: Mar 2026 to Dec 30, 2026
    v3
  2. Start date changed from estimate of Feb 2025 to Feb 1, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Trial Details
NCT Number NCT06853015
Lead Sponsor Shirley Ryan AbilityLab
Conditions
(from sponsor)		 SCI - Spinal Cord Injury
Related terms Spinal Cord Injuries
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov